This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Icon (ICLR)

Tipranks - Fri Jun 26, 8:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCA Healthcare (HCA) and Icon (ICLR) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

HCA Healthcare (HCA)

TD Cowen analyst Ryan Langston maintained a Buy rating on HCA Healthcare today and set a price target of $431.00. The company’s shares closed last Thursday at $384.75.

According to TipRanks.com, Langston is a 1-star analyst with an average return of -2.5% and a 43.9% success rate. Langston covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Privia Health Group, and P3 Health Partners. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HCA Healthcare with a $488.17 average price target, which is a 25.9% upside from current levels. In a report issued on June 10, TipRanks – PerPlexity also upgraded the stock to Buy with a $408.00 price target.

See today’s best-performing stocks on TipRanks >>

Icon (ICLR)

Deutsche Bank analyst Justin Bowers maintained a Buy rating on Icon today and set a price target of $188.00. The company’s shares closed last Thursday at $161.84.

According to TipRanks.com, Bowers is a 1-star analyst with an average return of -1.4% and a 43.8% success rate. Bowers covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., Maravai Lifesciences Holdings, and Fortrea Holdings Inc. ;'>

Icon has an analyst consensus of Moderate Buy, with a price target consensus of $174.25, which is a 10.2% upside from current levels. In a report released today, RBC Capital also upgraded the stock to Buy with a $185.00 price target.

Read More on HCA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.